hotspot -WSS

hotspot

author：focus 2025-10-02 12:01:48 - browse：5276

Emergent BioSolutions, the manufacturing company that fell into hot water in 2021 due to a contamination issue involving millions of doses of Covid vaccines, is pivoting its business and cutting hundreds of jobs, including a C-suite role.

The company announced Tuesday that it will cut 400 jobs and eliminate the role of chief operating officer as part of a shift away from its contract manufacturing services business. The current chief operating officer, Adam Havey, will leave the company on Sept. 30.

Instead, Emergent will focus on producing Narcan nasal spray and other products. The overdose reversal medicine became available as an over-the-counter medicine earlier this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Why Novartis is changing the name of its research labs

WSS

Why did Pfizer dish out millions for a Super Bowl ad?

Advances in CAR

Medicaid rebukes states for mistakenly disenrolling children

Ethical issues complicate the benefits of medical crowdfunding

Covid hospitalizations on the rise, Humana says

What we’ve learned from the Aduhelm mess

explore

hotspot

focus

Novavax promises a turnaround & Lilly roils the obesity market

How to fix cancer clinical trials' diversity problem

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD podcast: How biotech is using artificial intelligence

Supreme Court strikes down use of affirmative action

'Revelatory' study finds a smoking impact that remains after quitting

Wildfire smoke exposes gaps in outdoor worker protections

The (many) problems with a new study criticizing cancer screening

Hepatitis C has a cure — but many Americans still lack access to it

Medicaid rebukes states for mistakenly disenrolling children

hotspot

What should King Charles tell the public about his cancer?

PhRMA lawsuit over Medicare drug price negotiation tossed

BioAge raises $170M for combination therapy with Zepbound

Snackable artificial intelligence, expert AI, and the pharma industry

Gilead might be held responsible for not developing a drug

A rare thyroid diagnosis led to unexpected, all

explore

knowledge

leisure time

explore